Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005203947
Wed, 03.09.2025
BRAIN Biotech AG
BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business
ZWINGENBERG, Germany, September 3, 2025 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, has appointed Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocat [ … ]
Thu, 28.08.2025
BRAIN Biotech AG
BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts
BRAINBiocatalysts with +8.1% year-on-year revenue growth
Perillic Active project from the BRAINBioIncubator segment now successfully partnered
Cash position remains solid at €10.5 million
ZWINGENBERG, Germany, August 28, 2025 – BRAIN Biotech AG, a leading provider [ … ]
Mon, 25.08.2025
BRAIN Biotech AG
Corbion and BRAIN Biotech team to shape the future of innovation in nature-based ingredient technologies
ZWINGENBERG, Germany, August 25, 2025 – Corbion, the global sustainable ingredients company based in Amsterdam, the Netherlands, and BRAIN Biotech AG, headquartered in Zwingenberg, Germany, have reached agreement to collaborate in the developme [ … ]
Wed, 23.07.2025
BRAIN Biotech AG
Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG
ZWINGENBERG, Germany, July 23, 2025 – The Supervisory Board of BRAIN Biotech AG is once again fully staffed: Dr. Ursula La Cognata has been appointed as a new member of the 6-person Supervisory Board by the Darmstadt District Court with effect from July 11, 2025 until [ … ]
Wed, 28.05.2025
BRAIN Biotech AG
BRAIN Biotech AG reports final half-year figures for fiscal year 2024/25
BRAINBiocatalysts experienced modest organic growth in the first half of the year
BRAINBioIncubator with high basis for comparison in the previous year
Strong liquidity maintained at €14.9 million
ZWINGENBERG, Germany, May 28, 2025 – BRAIN Biotech AG, a leading provider of [ … ]
Tue, 20.05.2025
BRAIN Biotech AG
BRAIN Biotech announces buy-out of minorities, new continental European production site, and expansion of its Baking Application Center
Breatec B.V. is now fully owned by BRAIN Biotech AG following a minority buyout
New and enlarged production site will open close to Eindhoven, NL
Expanded competence center for enzyme-based baking applications
Z [ … ]
Tue, 18.03.2025
BRAIN Biotech AG
Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG
ZWINGENBERG, March 18, 2025 – At today's Annual General Meeting of BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949), shareholders approved all agenda items with a broad majority. Dr. Anna C. Eichhorn and Stephen Catling [ … ]
Wed, 26.02.2025
BRAIN Biotech AG
BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division
BRAINBiocatalysts organic growth at 11 % in Q1
Quantitative guidance looking at strong growth and solid adjusted EBITDA margin for BRAINBiocatalysts in FY 2024/25
Strong cash position maintained at € 17.8 million while reducing [ … ]
Thu, 13.02.2025
BRAIN Biotech AG
Biological gold recycling: BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative
Development of BioXtractor V2 pilot by BRAIN and PX Group and production of first BioGold nuggets from a local waste stream
Extension of cooperation between the two companies as part of the PX Urban Mining Initiative
PX Urban Mining Initiativ [ … ]
Wed, 15.01.2025
BRAIN Biotech AG
Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects
Group cash and cash equivalents improved to € 27.2 million
Successfully closed two milestone transactions with Royalty Pharma and Akribion Therapeutics
Management sees a strong start to the new financial year
Updated mid-term tar [ … ]
